Clinical Trials Logo

Poliomyelitis clinical trials

View clinical trials related to Poliomyelitis.

Filter by:

NCT ID: NCT06442449 Not yet recruiting - Poliomyelitis Clinical Trials

Booster Dose of sIPV Co-administered With MMR and HepA-I.

Start date: July 10, 2024
Phase: Phase 4
Study type: Interventional

This is an Open-labeled, Randomized, Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of Booster Dose of Sabin Strain Inactivated Poliovirus Vaccine (Vero cell) (sIPV) Co-administered with Measles, Mumps, Rubella (MMR) Combined Live Attenuated Vaccine and Inactivated Hepatitis A (Hep-A) Vaccine.

NCT ID: NCT06346834 Not yet recruiting - Poliomyelitis Clinical Trials

Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers

Start date: April 30, 2024
Phase: Phase 4
Study type: Interventional

To evaluate the immunogenicity and safety of sequential vaccination with Sinovac sIPV among infants who have received two doses of Biological Products Co., Ltd. sIPV.

NCT ID: NCT06162104 Completed - Fatigue Clinical Trials

Evaluation of Fatigue Severity, Mood, and Quality of Life in Post-Polio Syndrome

Start date: December 1, 2023
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to investigate the differences in the severity of fatigue, impact on quality of life, and mood between individuals with post-polio syndrome and healthy volunteer groups. Additionally, the interrelationships of these parameters within the post-polio syndrome patient group will be examined. The goal is to raise awareness during the follow-up process for individuals with post-polio syndrome by questioning fatigue and mood symptoms, and to facilitate the implementation of necessary precautions.

NCT ID: NCT06137664 Not yet recruiting - Poliomyelitis Clinical Trials

Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines

Start date: March 29, 2025
Phase: Phase 1/Phase 2
Study type: Interventional

The main objectives of this study are to : - evaluate the safety and tolerability of trivalent novel oral poliovirus vaccines (tnOPV) in healthy adults, young children, and neonates, relative to those receiving control vaccines; - evaluate the safety and tolerability of combined novel oral poliovirus vaccine type 1 (nOPV1) + novel oral poliovirus vaccine type 2 (nOPV2) in neonates, relative to those receiving the bivalent (types 1 and 3) oral poliovirus vaccine (bOPV) control. - compare type-specific antibody responses among all tnOPV dose combinations, following 4 vaccinations in healthy neonates; - evaluate the type-specific and overall antibody response among healthy neonates following 4 doses of combined nOPV1+nOPV2.

NCT ID: NCT06101173 Active, not recruiting - Poliomyelitis Clinical Trials

A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults

Start date: January 15, 2024
Phase: Phase 1
Study type: Interventional

This is a randomized, observer-blind, positive-controlled study. There will be 3 treatment groups, in each treatment group, participants will be randomly assigned to receive either investigational vaccine (Low-adjuvant dose VLP-Polio, Medium dose VLP-Polio, or High dose VLP-Polio that are defined as Dose A, Dose M, and Dose H, respectively) or control vaccine in a ratio of 3:1 in each group. Distribution of participant's gender should be balanced in each group.

NCT ID: NCT06058429 Active, not recruiting - Polio Clinical Trials

Immunogenicity of After Primary Immunization and Booster Immunization of sIPV

Start date: August 16, 2023
Phase:
Study type: Observational

This study was conducted on the basis of "Safety Observation of Sabin Strain Inactivated Polio Vaccine (Vero Cell) on primary Immunization, Booster Immunization and Simultaneous Vaccination with Other Vaccines in Infants and Young Children(ID: PRO-sIPV-MA4001-JX). Blood samples were collected in about 200 qualified subjects 1-9 months after their last vaccination of sIPV. And immunogenicity of sIPV and other vaccines simultaneously administrated will be tested, the antibodies against enterovirus (including EV71、CA16、CA6 and CA10) will also be tested.

NCT ID: NCT05952596 Not yet recruiting - Hepatitis B Clinical Trials

A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults

Start date: July 17, 2023
Phase: Phase 1
Study type: Interventional

This is a single-center, randomized, active-controlled, parallel-design, double-blind, phase I study to evaluate the safety and immunogenicity of a single dose of APV006 in healthy adults.

NCT ID: NCT05951985 Recruiting - Stroke Clinical Trials

High Intensity Functional Training for Individuals With Neurologic Diagnoses and Their Care Partners

SHIFT-AR
Start date: August 15, 2023
Phase: N/A
Study type: Interventional

Individuals with and without neurologic diagnoses greatly benefit from participation in regular exercise but the majority are physically inactive. This is an issue for both them and their care partners as their health is often linked. This study aims to examine the long-term physical and psychosocial effects of structured, group-based, high intensity functional training (HIFT) exercise for people with neurologic diagnoses and their care partners.

NCT ID: NCT05850364 Recruiting - Poliomyelitis Clinical Trials

A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine

Start date: May 22, 2023
Phase: Phase 3
Study type: Interventional

This study is designed to study the immunogenicity and safety of sIPV co-administered with other routine infant vaccines. According to the national immunization schedule of Bangladesh and Pakistan, sIPV was administered concomitantly with PCV10, DTP-HeB-Hib and other vaccines at 6, 10 and 14 weeks old. Thus, this study set up the concomitant vaccination schedule according to the real practice in study area. The primary hypothesis of this study is the seroconversion rate of polio vaccination when administered concomitantly with routine vaccines, is non-inferior to that when administered alone; the secondary hypothesis of this study is the seropositivity rate of diphtheria, tetanus, and pertussis when routine vaccines are administered concomitantly with sIPV, is non-inferior to that administered without sIPV.

NCT ID: NCT05721274 Completed - Polio Clinical Trials

Community Engagement and Conditional Incentives to Accelerate Polio

GLIDE
Start date: December 1, 2022
Phase: N/A
Study type: Interventional

Immunization is one of the most cost-effective and successful public health strategy in reducing the health, economic and societal burden of many infectious diseases. Pakistan and Afghanistan remain the only countries where polio is endemic, and Pakistan reports the most cases in the world. Although the rate is lower than in previous years, the situation remains alarming. This study objective is to decrease polio vaccine refusals and zero-dose vaccines by motivating behaviour change